Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The Company’s xMAP® multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics markets. The Company’s xMAP Technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies.
Through its Luminex Molecular Diagnostics entity, the company develops, manufactures and markets a franchise of molecular diagnostic assays for human genetic disorders, infectious disease and pharmacogenomic applications. xTAG RVP is the first FDA-cleared assay to simultaneously detect and differentiate 12 viruses and viral subtypes that together are responsible for more than 85 percent of respiratory viral infections1. It is the first multiplexed nucleic acid test for respiratory viruses cleared for in vitro diagnostic use by the FDA. It also is the first test of any kind cleared to detect human metapneumovirus, the first test cleared for influenza A subtyping, and the first molecular test cleared for adenovirus.
Further information on Luminex Corporation or xMAP Technology can be obtained at www.luminexcorp.com.
References:
1. Mahony J., et al. Establishing the Epidemiology of Respiratory Virus Infections Using Molecular Technology, Poster presented at the 107th ASM Meeting.